Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Chinese Herbal Compound TJAOA101 in Treatment of Diminished Ovarian Reserve: a Prospective, Multi-center and Before-after Study.

NCT05459493 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05459493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05459493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Chinese Herbal Compound TJAOA101 in Treatment of Diminished Ovarian Reserve: a Prospective, Multi-center and Before-after Study.
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 1, 2022
Completion date
November 1, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diminished ovarian reserve